Sfoglia per Autore
Prognostic value of CD133 caused by mutant K-Ras and B-Raf
2012-01-01 Fornaro, L; Crea, F; Masi, G; DI PAOLO, Antonello; Vivaldi, C; Danesi, Romano; Falcone, Alfredo
Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?
2012-01-01 Fornaro, L; Masi, G; Caparello, C; Vivaldi, C; Falcone, Alfredo
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO).
2012-01-01 Salvatore, L; Masi, G; Loupakis, F; Cremolini, Chiara; Schirripa, M; Fornaro, L; Antoniotti, C; Vivaldi, C; Granetto, C; Fea, E; Antonuzzo, L; Giommoni, E; Boni, C; Banzi, M; Chiara, S; Sonaglio, C; Allegrini, G; Marcucci, L; Valsuani, C; Greco, F; Safina, V; Boni, L; Falcone, Alfredo
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples.
2012-01-01 Vivaldi, C; Crea, F; Fornaro, L; Faviana, Pinuccia; Masi, G; DE GREGORIO, V; Paolicchi, E; Sensi, E; Lupi, C; Fontanini, Gabriella; Danesi, Romano; Falcone, Alfredo
Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter.
2012-01-01 Fornaro, L; Crea, F; Masi, G; DI PAOLO, Antonello; Vivaldi, C; Danesi, Romano; Falcone, Alfredo
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment.
2013-01-01 Pantano, F.; Guida, F. M.; Vivaldi, C.; Vincenzi, B.; Grande, E.; Garrote, M. R.; Caraglia, M.; Silvestris, N.; Vasile, E.; Goletti, Orlando; Falcone, Alfredo; Tonini, G.; Santini, D.
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
2013-01-01 Fornaro, L; Lonardi, S; Masi, G; Loupakis, F; Bergamo, F; Salvatore, L; Cremolini, Chiara; Schirripa, M; Vivaldi, C; Aprile, G; Zaniboni, A; Bracarda, S; Fontanini, Gabriella; Sensi, E; Lupi, C; Morvillo, M; Zagonel, V; Falcone, Alfredo
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
2013-01-01 Fornaro, L.; Lonardi, S.; Masi, G.; Loupakis, Fotios; Bergamo, F.; Salvatore, L.; Cremolini, Chiara; Schirripa, M.; Vivaldi, C.; Aprile, G.; Zaniboni, A.; Bracarda, S.; Fontanini, Gabriella; Sensi, E.; Lupi, C.; Morvillo, M.; Zagonel, V.; Falcone, Alfredo
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction
2014-01-01 Petrini, Iacopo; Lencioni, M; Vasile, E; Begliuomini, L; Ginocchi, Laura; Caparello, Chiara; Musettini, Gianna; Vivaldi, Caterina; Caponi, S; Proietti, Agnese; Fontanini, Gabriella; Naccarato, ANTONIO GIUSEPPE; Santi, S; Falcone, Alfredo
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.
2014-01-01 Fornaro, L.; Vivaldi, C.; Caparello, C.; Sacco, R.; Rotella, V.; Musettini, G.; Luchi, S.; Baldini, E.; Falcone, Alfredo; Masi, G.
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
2014-01-01 Fornaro, L.; Cereda, S.; Aprile, G.; Di Girolamo, S.; Santini, D.; Silvestris, N.; Lonardi, S.; Leone, F.; Milella, M.; Vivaldi, C.; Belli, C.; Bergamo, F.; Lutrino, S. E.; Filippi, R.; Russano, M.; Vaccaro, V.; Brunetti, A. E.; Rotella, V.; Falcone, Alfredo; Barbera, M. A.; Corbelli, J.; Fasola, G.; Aglietta, M.; Zagonel, V.; Reni, M.; Vasile, E.; Brandi, G.
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review.
2014-01-01 Fornaro, L.; Caparello, C.; Vivaldi, C.; Rotella, V.; Musettini, G.; Falcone, Alfredo; Baldini, E.; Masi, G.
Second-line chemotherapy in advanced biliary cancer: The present now will later be past
2014-01-01 Vivaldi, C.; Fornaro, L.; Cereda, S.; Aprile, G.; Santini, D.; Silvestris, N.; Lonardi, S.; Leone, F.; Milella, M.; Brandi, G.; Vasile, E.
Not only chemotherapy in the second-line treatment of metastatic gastric cancer.
2014-01-01 Vasile, E.; Caparello, C.; Caponi, S.; Ginocchi, L.; Vivaldi, C.; Lucchesi, G. Musettini M.; Lencioni, M.; Falcone, Alfredo
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense?
2015-01-01 Musettini, Gianna; Caparello, Chiara; Vivaldi, Caterina; Pasquini, G.; Lencioni, Martina; Petrini, Iacopo; Fornaro, L.; Vasile, E.; Falcone, Alfredo
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox)
2015-01-01 Vivaldi, Caterina; Vasile, E.; Fornaro, L.; Pasquini, G.; Catanese, S.; Caparello, Chiara; Musettini, Gianna; Lencioni, Martina; Ricci, S.; Falcone, Alfredo
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now?
2015-01-01 Fornaro, L.; Cereda, S.; Leone, Francesco; Aprile, G.; Lonardi, Sara; Silvestris, N.; Santini, D.; Milella, M.; Palloni, A.; Barbera, A.; Ferrai, L.; Filippi, R.; Bergamo, F.; Vivaldi, Caterina; Caparello, Chiara; Musettini, Gianna; Pasquini, G.; Falcone, Alfredo; Reni, M.; Brandi, G.; Vasile, E. .
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer.
2015-01-01 Caparello, Chiara; Vasile, E.; Fornaro, L.; Lencioni, Martina; Petrini, Iacopo; Vivaldi, Caterina; Pasquini, G.; Musettini, Gianna; Falcone, Alfredo
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients.
2015-01-01 Pasquini, G.; Fornaro, L.; Vasile, E.; Lencioni, M.; Petrini, Iacopo; Caparello, Chiara; Vivaldi, Caterina; Musettini, Gianna; Falcone, Alfredo
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
2015-01-01 Fornaro, L.; Vivaldi, Caterina; Cereda, S.; Leone, F.; Aprile, G.; Lonardi, S.; Silvestris, N.; Santini, D.; Milella, M.; Caparello, Chiara; Musettini, Gianna; Pasquini, G.; Falcone, Alfredo; Brandi, G.; Sperduti, I.; Vasile, E. .
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Prognostic value of CD133 caused by mutant K-Ras and B-Raf | 1-gen-2012 | Fornaro, L; Crea, F; Masi, G; DI PAOLO, Antonello; Vivaldi, C; Danesi, Romano; Falcone, Alfredo | |
| Resectable liver metastases from colorectal cancer: where we are now and where do we go from here? | 1-gen-2012 | Fornaro, L; Masi, G; Caparello, C; Vivaldi, C; Falcone, Alfredo | |
| A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). | 1-gen-2012 | Salvatore, L; Masi, G; Loupakis, F; Cremolini, Chiara; Schirripa, M; Fornaro, L; Antoniotti, C; Vivaldi, C; Granetto, C; Fea, E; Antonuzzo, L; Giommoni, E; Boni, C; Banzi, M; Chiara, S; Sonaglio, C; Allegrini, G; Marcucci, L; Valsuani, C; Greco, F; Safina, V; Boni, L; Falcone, Alfredo | |
| Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. | 1-gen-2012 | Vivaldi, C; Crea, F; Fornaro, L; Faviana, Pinuccia; Masi, G; DE GREGORIO, V; Paolicchi, E; Sensi, E; Lupi, C; Fontanini, Gabriella; Danesi, Romano; Falcone, Alfredo | |
| Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter. | 1-gen-2012 | Fornaro, L; Crea, F; Masi, G; DI PAOLO, Antonello; Vivaldi, C; Danesi, Romano; Falcone, Alfredo | |
| Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. | 1-gen-2013 | Pantano, F.; Guida, F. M.; Vivaldi, C.; Vincenzi, B.; Grande, E.; Garrote, M. R.; Caraglia, M.; Silvestris, N.; Vasile, E.; Goletti, Orlando; Falcone, Alfredo; Tonini, G.; Santini, D. | |
| FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). | 1-gen-2013 | Fornaro, L; Lonardi, S; Masi, G; Loupakis, F; Bergamo, F; Salvatore, L; Cremolini, Chiara; Schirripa, M; Vivaldi, C; Aprile, G; Zaniboni, A; Bracarda, S; Fontanini, Gabriella; Sensi, E; Lupi, C; Morvillo, M; Zagonel, V; Falcone, Alfredo | |
| Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). | 1-gen-2013 | Fornaro, L.; Lonardi, S.; Masi, G.; Loupakis, Fotios; Bergamo, F.; Salvatore, L.; Cremolini, Chiara; Schirripa, M.; Vivaldi, C.; Aprile, G.; Zaniboni, A.; Bracarda, S.; Fontanini, Gabriella; Sensi, E.; Lupi, C.; Morvillo, M.; Zagonel, V.; Falcone, Alfredo | |
| EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction | 1-gen-2014 | Petrini, Iacopo; Lencioni, M; Vasile, E; Begliuomini, L; Ginocchi, Laura; Caparello, Chiara; Musettini, Gianna; Vivaldi, Caterina; Caponi, S; Proietti, Agnese; Fontanini, Gabriella; Naccarato, ANTONIO GIUSEPPE; Santi, S; Falcone, Alfredo | |
| Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. | 1-gen-2014 | Fornaro, L.; Vivaldi, C.; Caparello, C.; Sacco, R.; Rotella, V.; Musettini, G.; Luchi, S.; Baldini, E.; Falcone, Alfredo; Masi, G. | |
| Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. | 1-gen-2014 | Fornaro, L.; Cereda, S.; Aprile, G.; Di Girolamo, S.; Santini, D.; Silvestris, N.; Lonardi, S.; Leone, F.; Milella, M.; Vivaldi, C.; Belli, C.; Bergamo, F.; Lutrino, S. E.; Filippi, R.; Russano, M.; Vaccaro, V.; Brunetti, A. E.; Rotella, V.; Falcone, Alfredo; Barbera, M. A.; Corbelli, J.; Fasola, G.; Aglietta, M.; Zagonel, V.; Reni, M.; Vasile, E.; Brandi, G. | |
| Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. | 1-gen-2014 | Fornaro, L.; Caparello, C.; Vivaldi, C.; Rotella, V.; Musettini, G.; Falcone, Alfredo; Baldini, E.; Masi, G. | |
| Second-line chemotherapy in advanced biliary cancer: The present now will later be past | 1-gen-2014 | Vivaldi, C.; Fornaro, L.; Cereda, S.; Aprile, G.; Santini, D.; Silvestris, N.; Lonardi, S.; Leone, F.; Milella, M.; Brandi, G.; Vasile, E. | |
| Not only chemotherapy in the second-line treatment of metastatic gastric cancer. | 1-gen-2014 | Vasile, E.; Caparello, C.; Caponi, S.; Ginocchi, L.; Vivaldi, C.; Lucchesi, G. Musettini M.; Lencioni, M.; Falcone, Alfredo | |
| Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? | 1-gen-2015 | Musettini, Gianna; Caparello, Chiara; Vivaldi, Caterina; Pasquini, G.; Lencioni, Martina; Petrini, Iacopo; Fornaro, L.; Vasile, E.; Falcone, Alfredo | |
| Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) | 1-gen-2015 | Vivaldi, Caterina; Vasile, E.; Fornaro, L.; Pasquini, G.; Catanese, S.; Caparello, Chiara; Musettini, Gianna; Lencioni, Martina; Ricci, S.; Falcone, Alfredo | |
| Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? | 1-gen-2015 | Fornaro, L.; Cereda, S.; Leone, Francesco; Aprile, G.; Lonardi, Sara; Silvestris, N.; Santini, D.; Milella, M.; Palloni, A.; Barbera, A.; Ferrai, L.; Filippi, R.; Bergamo, F.; Vivaldi, Caterina; Caparello, Chiara; Musettini, Gianna; Pasquini, G.; Falcone, Alfredo; Reni, M.; Brandi, G.; Vasile, E. . | |
| Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. | 1-gen-2015 | Caparello, Chiara; Vasile, E.; Fornaro, L.; Lencioni, Martina; Petrini, Iacopo; Vivaldi, Caterina; Pasquini, G.; Musettini, Gianna; Falcone, Alfredo | |
| Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. | 1-gen-2015 | Pasquini, G.; Fornaro, L.; Vasile, E.; Lencioni, M.; Petrini, Iacopo; Caparello, Chiara; Vivaldi, Caterina; Musettini, Gianna; Falcone, Alfredo | |
| Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data | 1-gen-2015 | Fornaro, L.; Vivaldi, Caterina; Cereda, S.; Leone, F.; Aprile, G.; Lonardi, S.; Silvestris, N.; Santini, D.; Milella, M.; Caparello, Chiara; Musettini, Gianna; Pasquini, G.; Falcone, Alfredo; Brandi, G.; Sperduti, I.; Vasile, E. . |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile